Monte Rosa Therapeutics I... (GLUE)

5.62

0.12 (2.18%)

At close: Mar 03, 2025, 12:38 PM

Monte Rosa Therapeutics Cash Flow Statement

Table Mode

Year	FY23	FY22	FY21	FY20	FY19
Net Income	-135.35M	-108.5M	-73.96M	-35.88M	-7.74M
Depreciation & Amortization	6.22M	3.75M	2.13M	537K	72K
Stock-Based Compensation	16.67M	11.66M	5.2M	354K	n/a
Other Working Capital	64.81M	-1.39M	6.99M	820K	-1.09M
Other Non-Cash Items	-3.81M	2.76M	960K	7.68M	-276K
Deferred Income Tax	n/a	n/a	17K	n/a	n/a
Change in Working Capital	72.47M	-2.13M	6.29M	4.25M	1.77M
Operating Cash Flow	-43.8M	-92.47M	-59.36M	-23.05M	-6.17M
Capital Expenditures	-19.04M	-12.91M	-9.73M	-3.39M	-1.39M
Acquisitions	n/a	109K	79K	n/a	n/a
Purchase of Investments	-103.15M	-384.42M	n/a	n/a	n/a
Sales Maturities Of Investments	210.93M	178M	n/a	n/a	n/a
Other Investing Acitivies	62K	-206.31K	79.00	n/a	n/a
Investing Cash Flow	88.8M	-219.22M	-9.65M	-3.39M	-1.39M
Debt Repayment	n/a	n/a	n/a	n/a	750K
Common Stock Repurchased	n/a	n/a	n/a	-440K	n/a
Dividend Paid	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	27.49M	411K	139.81M	60.5M	14.25M
Financial Cash Flow	27.49M	20.47M	377.56M	60.06M	15M
Net Cash Flow	72.49M	-291.22M	308.55M	33.62M	7.44M
Free Cash Flow	-62.84M	-105.38M	-69.09M	-26.44M	-7.56M